Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT01398111
- Locations
- 🇧🇪
Clinical Pharmacology Unit - SGS Life Science Services, Antwerpen, Lange Beeldekensstraat 267, Belgium
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01391559
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Efficacy of Indacaterol 150 µg Versus Formoterol
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01377428
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT01360021
- Locations
- 🇷🇺
Research Site, Moscow, Russia, Russian Federation
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 1070
- Registration Number
- NCT01290874
- Locations
- 🇺🇸
G.A. Carmichael F.H.C., Canton, Mississippi, United States
🇺🇸Edward Waters College Medical Center (Mayo), Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT01218399
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Yale University
- Target Recruit Count
- 14
- Registration Number
- NCT01194479
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 109
- Registration Number
- NCT01048333
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 457
- Registration Number
- NCT00972140
- Locations
- 🇵🇱
Prof. Iwona Graelewska Rzymowska, Lodz, Lódz, Poland
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 329
- Registration Number
- NCT00929708
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.